StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
17
Publishing Date
2022 - 09 - 29
1
2022 - 07 - 07
1
2022 - 07 - 06
1
2022 - 06 - 09
1
2022 - 05 - 23
1
2022 - 02 - 22
1
2022 - 02 - 14
1
2022 - 01 - 18
1
2021 - 12 - 06
1
2021 - 11 - 15
1
2021 - 10 - 27
1
2021 - 09 - 27
1
2021 - 06 - 23
1
2021 - 03 - 29
1
2021 - 03 - 10
1
2021 - 01 - 18
1
2021 - 01 - 04
1
Sector
Health technology
17
Tags
Alliances
2
Als
3
Alzheimer
1
Alzheimer's
1
Alzheimer's disease
1
Alzheimer’s
1
Antibody
1
Application
2
Approval
4
Authorization
1
Bhv-7000
1
Bio-nc
1
Bioscience
2
Biotech-bay
1
Biotechnology
1
Business
5
Clinical-trials-phase-ii
2
Clinical-trials-phase-iii
2
Collaboration
4
Commercialization
2
Conference
2
Disease
3
Drug
3
Earnings
11
Enroll
5
Ev
4
Events
3
Fda
2
Financial
6
Financial results
10
Health
2
Label
2
License
4
Meeting
3
Mergers-and-acquisitions
2
Migraine
24
Money
2
Muscular atrophy
2
N/a
58
Nurtec
8
Offering
11
Pharm-country
16
Pharmaceutical
2
Phase 1
2
Phase 2
6
Phase 2/3
3
Phase 3
8
Platform
4
Positive
3
Presentation
5
Report
5
Research
5
Results
26
Therapeutics
3
Therapy
2
Topline
2
Topline results
2
Treatment
17
Trial
17
Update
2
Entities
4d molecular therapeutics inc
21
Abb ltd
72
Abbvie inc.
32
Achieve life sciences, inc.
21
Actinium pharmaceuticals, inc.
25
Aldeyra therapeutics, inc.
32
Alterity therapeutics limited
26
Altra industrial motion corp.
23
Alzamend neuro inc
20
Anavex life sciences corp.
21
Arcutis biotherapeutics, inc.
22
Arrival
21
Ascendis pharma a/s
20
Astellas pharma inc
22
Astrazeneca plc
52
Axsome therapeutics, inc.
20
Beigene, ltd.
23
Biovie inc.
23
Bioxcel therapeutics, inc.
25
Bristol-myers squibb company
48
Clearside biomedical, inc.
22
Cnh industrial n.v.
69
Cytokinetics, incorporated
24
Dynavax technologies corporation
23
Eli lilly and company
116
Enlivex therapeutics ltd.
24
Exelixis, inc.
28
Fortress biotech, inc.
29
Gates industrial corporation plc
25
Gilead sciences, inc.
23
Global industrial co
37
Honeywell international inc.
53
Horizon therapeutics public limited company
35
Hutchison china meditech limited
22
I-mab
21
Icon plc
26
Immix biopharma, inc.
23
Immunic, inc.
21
Immutep limited
25
Incyte corporation
28
Johnson & johnson
99
Johnson controls international plc
22
Merck & company, inc.
45
Moleculin biotech, inc.
30
Novartis ag
25
Novo nordisk a/s
32
Novocure limited
22
Ocugen, inc.
23
Orange
66
Pds biotechnology corporation
22
Pfizer, inc.
47
Plus therapeutics, inc.
29
Regeneron pharmaceuticals, inc.
30
Regenxbio inc.
27
Sanofi
165
Sellas life sciences group, inc.
23
Sorrento therapeutics, inc.
33
Stag industrial, inc.
32
Takeda pharmaceutical company limited
36
Thermo fisher scientific inc
28
Symbols
BHVN
17
PFE
1
Exchanges
Nyse
17
Crawled Date
2022 - 09 - 29
1
2022 - 07 - 07
1
2022 - 07 - 06
1
2022 - 06 - 09
1
2022 - 05 - 23
1
2022 - 02 - 22
1
2022 - 02 - 14
1
2022 - 01 - 18
1
2021 - 12 - 06
1
2021 - 11 - 15
1
2021 - 10 - 27
1
2021 - 09 - 27
1
2021 - 06 - 23
1
2021 - 03 - 29
1
2021 - 03 - 11
1
2021 - 01 - 18
1
2021 - 01 - 04
1
Crawled Time
00:05
1
07:00
1
12:00
4
12:30
1
13:00
3
13:07
1
13:20
1
13:30
1
15:00
2
20:00
1
22:00
1
Source
www.biospace.com
11
www.prnewswire.com
6
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Trial
entities :
Biohaven pharmaceutical holding company ltd.
save search
Biohaven Provides Update From Pivotal Phase 2/3 Trial with Verdiperstat in Amyotrophic Lateral Sclerosis (Healy ALS Platform Trial)
Published:
2022-09-29
(Crawled : 13:20)
- biospace.com/
BHVN
1 d
|
$38.99
-7.52%
0.0%
3.4M
|
Health Technology
|
-72.25%
|
O:
-0.19%
H:
0.12%
C:
-0.07%
als
trial
update
sclerosis
platform
phase 2
Biohaven Enrolls First Patient in Phase 3 Trial of Taldefgrobep alfa in Spinal Muscle Atrophy (SMA)
Published:
2022-07-07
(Crawled : 12:00)
- prnewswire.com
BHVN
1 d
|
$38.99
-7.52%
0.0%
3.4M
|
Health Technology
|
-71.05%
|
O:
-0.11%
H:
0.14%
C:
-0.17%
trial
phase 3
Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven’s Troriluzole and Vigeo’S VT1021 in GBM AGILE Trial
Published:
2022-07-06
(Crawled : 20:00)
- biospace.com/
BHVN
1 d
|
$38.99
-7.52%
0.0%
3.4M
|
Health Technology
|
-71.12%
|
O:
-0.01%
H:
0.26%
C:
-0.26%
vt1021
trial
Biohaven Underscores Depth of Migraine Portfolio with Data from Nurtec® ODT (rimegepant) Long-Term Open Label Study and Phase 3 Zavegepant Trial at 64th Annual Scientific Meeting of the American Headache Society
Published:
2022-06-09
(Crawled : 13:00)
- biospace.com/
BHVN
1 d
|
$38.99
-7.52%
0.0%
3.4M
|
Health Technology
|
-70.93%
|
O:
-0.08%
H:
0.25%
C:
-0.26%
nurtec
label
trial
migraine
phase 3
Biohaven Provides Update on Phase 3 Clinical Trial Evaluating Troriluzole for Spinocerebellar Ataxia (SCA)
Published:
2022-05-23
(Crawled : 12:00)
- biospace.com/
BHVN
1 d
|
$38.99
-7.52%
0.0%
3.4M
|
Health Technology
|
-70.17%
|
O:
0.25%
H:
1.91%
C:
0.92%
trial
phase 3
Biohaven Enrolls First Patient in Phase 2/3 Sinusitis Trial of Nurtec® ODT
Published:
2022-02-22
(Crawled : 13:00)
- prnewswire.com
BHVN
1 d
|
$38.99
-7.52%
0.0%
3.4M
|
Health Technology
|
-69.8%
|
O:
-1.15%
H:
1.44%
C:
-2.83%
nurtec
phase 2
phase 2/3
trial
enroll
Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea
Published:
2022-02-14
(Crawled : 12:30)
- biospace.com/
PFE
A
|
$26.0
2.4%
-0.15%
38M
|
Health Technology
|
-49.94%
|
O:
-1.89%
H:
1.36%
C:
-0.04%
BHVN
1 d
|
$38.99
-7.52%
0.0%
3.4M
|
Health Technology
|
-68.73%
|
O:
0.27%
H:
2.86%
C:
1.95%
treatment
trial
migraine
china
topline results
positive
results
topline
Global Coalition for Adaptive Research Announces Key Updates on GBM AGILE Phase 2-3 Adaptive Platform Trial for Patients With Glioblastoma
Published:
2022-01-18
(Crawled : 22:00)
- biospace.com/
BHVN
1 d
|
$38.99
-7.52%
0.0%
3.4M
|
Health Technology
|
-65.49%
|
O:
-1.78%
H:
0.59%
C:
-1.67%
phase 2
research
trial
platform
glioblastoma
Biohaven Reports Positive Topline Results from Pivotal Migraine Trial of Intranasal Zavegepant Demonstrating Ultra-Rapid Pain Relief by 15 minutes; Prepares for Submission of New Drug Application
Published:
2021-12-06
(Crawled : 13:30)
- biospace.com/
BHVN
1 d
|
$38.99
-7.52%
0.0%
3.4M
|
Health Technology
|
-61.29%
|
O:
-5.67%
H:
0.0%
C:
0.0%
new drug
application
drug
trial
migraine
topline results
positive
results
topline
pain relief
submission
Biohaven Completes Enrollment Of Verdiperstat Arm Of Pivotal Healey ALS Platform Trial Conducted By The Healey Center For ALS At Massachussetts General Hospital
Published:
2021-11-15
(Crawled : 15:00)
- biospace.com/
BHVN
1 d
|
$38.99
-7.52%
0.0%
3.4M
|
Health Technology
|
-65.44%
|
O:
0.93%
H:
0.0%
C:
-4.17%
platform
trial
als
enroll
Biohaven Enrolls Phase 1a/1b Clinical Trial of BHV-1100, Lead Asset from its ARM™ (Antibody Recruiting Molecule) Platform, in Combination with NK Cell Therapy for the Treatment of Multiple Myeloma
Published:
2021-10-27
(Crawled : 12:00)
- prnewswire.com
BHVN
1 d
|
$38.99
-7.52%
0.0%
3.4M
|
Health Technology
|
-70.19%
|
O:
0.21%
H:
0.1%
C:
-3.26%
treatment
phase 1
therapy
antibody
trial
phase 1b
enroll
Biohaven Provides Update On Phase 3 Trial And Multiple System Atrophy (MSA) Program
Published:
2021-09-27
(Crawled : 12:00)
- biospace.com/
BHVN
1 d
|
$38.99
-7.52%
0.0%
3.4M
|
Health Technology
|
-69.12%
|
O:
-3.57%
H:
2.18%
C:
0.94%
phase 3
trial
Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven
Published:
2021-06-23
(Crawled : 07:00)
- prnewswire.com
BHVN
1 d
|
$38.99
-7.52%
0.0%
3.4M
|
Health Technology
|
-56.63%
|
O:
0.29%
H:
1.88%
C:
0.25%
phase 1
collaboration
trial
phase 2
phase 3
Biohaven Enrolls First Patient in Phase 2/3 Trial of Oral Zavegepant, Prompting $100 Million Milestone Funding Payment from Royalty Pharma
Published:
2021-03-29
(Crawled : 13:00)
- biospace.com/
BHVN
1 d
|
$38.99
-7.52%
0.0%
3.4M
|
Health Technology
|
-36.65%
|
O:
-1.52%
H:
0.82%
C:
-2.24%
funding
phase 2
phase 2/3
trial
enroll
milestone
Biohaven Announces Completion Of 50% Enrollment Ahead Of Timelines In Verdiperstat Pivotal HEALEY ALS Platform Trial At Massachusetts General Hospital
Published:
2021-03-10
(Crawled : 00:05)
- prnewswire.com
BHVN
1 d
|
$38.99
-7.52%
0.0%
3.4M
|
Health Technology
|
-44.48%
|
O:
2.38%
H:
4.18%
C:
2.68%
trial
als
enroll
Biohaven Provides Update On Phase 2/3 Trial And Alzheimer's Disease Program
Published:
2021-01-18
(Crawled : 15:00)
- biospace.com/
BHVN
1 d
|
$38.99
-7.52%
0.0%
3.4M
|
Health Technology
|
Email alert
Add to watchlist
disease
alzheimer
trial
phase 2
phase 2/3
alzheimer’s
alzheimer's disease
program
alzheimer's
Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder
Published:
2021-01-04
(Crawled : 13:07)
- prnewswire.com
BHVN
1 d
|
$38.99
-7.52%
0.0%
3.4M
|
Health Technology
|
-50.81%
|
O:
-0.01%
H:
1.19%
C:
-4.42%
phase 3
trial
Gainers vs Losers
67%
33%
Top 10 Gainers
AGBA
|
News
|
$1.26
215.0%
68.25%
130M
|
Finance
EGOX
|
$0.0515
43.06%
30.1%
330M
|
OLB
4
|
$0.33
-14.95%
25.53%
840K
|
Technology Services
NVFY
|
$2.77
31.28%
23.83%
33M
|
Consumer Durables
ZCMD
|
$1.87
28.97%
22.46%
31M
|
Commercial Services
RCON
|
$0.1112
13.01%
21.28%
1.7M
|
Distribution Services
INSG
|
$3.03
25.21%
20.13%
330K
|
Electronic Technology
GCTK
|
$0.8191
22.25%
18.2%
190K
|
Manufacturing
WLGS
|
$0.59
18.0%
17.9%
2.3M
|
ASNS
|
$0.828
21.75%
17.86%
18K
|
Your saved searches
Save your searches and get alerts when important news are released.